TOXICITY OF A TRADITIONAL CHINESE MEDICINE, GANODERMA LUCIDUM, IN CHILDREN WITH CANCER

Simerpal K Gill; Michael J Rieder

Simerpal K Gill

Departments of Paediatrics, Physiology and Pharmacology and Medicine, The University of Western Ontario, London, Ontario, Robarts Research Institute, London, Ontario

Michael J Rieder

Departments of Paediatrics, Physiology and Pharmacology and Medicine, The University of Western Ontario, London, Ontario, Robarts Research Institute, London, Ontario ;Children’s Health Research Institute, London, Ontario

Keywords

Ganoderma lucidum, Ling-zhi, Reishi, chemotherapy, paediatric cancer, immunotoxicity

Abstract

Background

Cancer is one of the most common severe diseases in Canadian children, and chemotherapy treatment leads to numerous, potentially fatal, adverse side effects including febrile neutropenia and leukopenia. In an attempt to prevent opportunistic infections, Ganoderma lucidum, a mushroom that has been used in Traditional Chinese Medicine for thousands of years, is being used by some people as an adjunctive to chemotherapy to help boost the immune system. Although extensive research is being conducted to determine its immunostimulatory properties, there is essentially no data on toxicity.

Objectives and Methods

The purpose of this study was to determine toxicity of low and high concentrations of 3 different extracts of G. lucidum (GL, Reishi and PSGL) on the viability of 1) Jurkat E6.1 cells, 2) LG2 cells, and 3) PBMCs isolated from a) healthy adults, b) healthy children, and c) paediatric patients undergoing chemotherapy.

Results

When Jurkat E6.1 and LG2 cells were treated with increasing concentrations of the 3 extracts, both time-and concentration- dependent decreases in cell viability were observed. However, when human PBMCs were treated with the same extracts, variable results were obtained. Although there was no consistent pattern, toxicity was observed in PBMCs.

Conclusion

This is the first study that examines the toxicity of 3 different extracts of G. lucidum in both adults’ and children’s PBMCs. Contrary to previous belief, our results suggest that extracts of G. lucidum should be used with caution as there appears to be potential for toxicity.

Abstract 1610 | PDF Downloads 580

References

1. Gao RN, Levy IG, Woods WG, Coombs BA, Gaudette LA, Hill GB. Incidence and mortality of neuroblastoma in Canada compared with other childhood cancers. Cancer Causes Control 1997;8:745-754.
2. Gao Y, Zhou S, Jiang W, Huang M, Dai X. Effects of Ganopoly ™ (A Ganoderma lucidumPolysaccharide Extract) on the Immune Functions in Advanced- Stage Cancer Patients. Immunol Invest 2003;32:201-215.
3. Phillips E. Hotspot: Advances and Challenges in the Management of Febrile Neutropenia. Rapid Response Radiotherapy Program 2001;4:1-2.
4. Johnston D, Nagel K, O’Halloran C, et al. Complementary and alternative medicine in pediatric oncology: availability and institutional policies in Canada – A report from the children’s oncology group. Pediatr Blood Cancer 2006;47:955-958.
5. Chan W, Lam D, Law H, et al. Ganoderma lucidum mycelium and spore extracts as natural adjuvants for immunotherapy. J Complem Altern Med 2005;6:1047 -1057.
6. Chen J, Chen T. Chinese Medical Herbology and Pharmacology. England: Art of Medicine Press, 2003.
7. Sliva D. Ganoderma lucidum (Reishi) in Cancer Treatment. Integr Cancer Ther 2003;2:358-364.
8. Shiao M. Natural products of the medicinal fungus Ganoderma lucidum: Occurrence, biological activities, and pharmacological functions. Chem Rec 2003;3:72- 180.
9. Zhang H, Lin Z. Hypoglycemic effect of Ganoderma lucidum polysaccharides. Acta Pharmacol Sin 2004;2:191 -195.
10. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. J Immunol Methods 1983;65:55 -63.
11. Bach M, Brashler J. Isolation of subpopulations of lymphocytic cells by the use of isotonically balanced solutions of Ficoll. I. Development of methods and demonstration of the existence of a large but finite number of subpopulations. Exp Cell Res 1970;61;387-396.
12. Bao XF, Wang XS, Dong Q, Fang JN, Li XY. Structural features of immunologically active polysaccharides from Ganoderma lucidium. Phytochemistry 2002;59:175 -181.
13. Wang Y, Khoo K, Chen S, Lin C, Wong C, Lin C. Studies on the Immuno-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 2002;10:1057- 1062.
14. Chen H, Tsai Y, Lin S, et al. Studies on the Immunomodulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg Med Chem 2004; 12:5595-5601.
15. Chien C, Cheng J, Chang W, et al. Polysaccharides of Ganoderma lucidum alter cell immunophenotypic expression and enhance CD56+ NK-cell cytotoxicity in cord blood. Bioorg Med Chem 2004; 12:5603- 5609.
16. Bao X, Fang J, Li X. Structural characterization and immunomodulating activity of a complex glucan from spores of Ganoderma lucidum. Biosci Biotechnol Biochem 2001;65:2384-2391.
17. Shao B, Dai H, Xu W, Lin Z, Gao X. Immune receptors for polysaccharides from Ganoderma lucidum. Biochem Biophys Res Commun 2004;323:133-141.
18. Lin Z, Zhang H. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and its possible mechanisms. Acta Pharmacol Sin 2004;11:1387 -1395.
19. Zhang J, Tang Q, Zimmerman-Kordmann M, Reutter W, Fan H. Activation of B lymphocytes by GLIS, a bioactive proteoglycan from Ganoderma lucidum. Life Sci 2002;71:623-638.

PDF

Published

Dec 8, 2018

How to Cite

K Gill, S., & J Rieder, M. (2018). TOXICITY OF A TRADITIONAL CHINESE MEDICINE, GANODERMA LUCIDUM, IN CHILDREN WITH CANCER. Journal of Population Therapeutics and Clinical Pharmacology, 15(2). Retrieved from https://jptcp.com/index.php/jptcp/article/view/215